Video

Dr. Swain Discusses the Final OS Analysis from the CLEOPATRA Study

Sandra M. Swain, MD, discusses final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.

Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses final overall survival (OS) analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.

Median OS was 40.8 months in the placebo arm and 56.5 months in the pertuzumab arm — a different of 15.7 months. This is truly a remarkable improvement, Swain says.

Monoclonal antibodies have changed the trajectory of the disease in many patients with HER2-positive metastatic breast cancer, Swain says, and they are now able to live fairly normal lives.

<<<

View more from the 2014 ESMO Congress

Related Videos
Ruth M. O’Regan, MD
Peter Forsyth, MD
Paolo Caimi, MD
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD